Optomed (OPTOMED) Q1 2026 earnings summary

Executive summary

• Achieved strongest quarter ever for Aurora AEYE new subscription sales, despite overall weak revenue development and temporary regulatory uncertainty.

• Revenue declined 16.7% year-over-year to €3.35 million, mainly due to timing effects and US regulatory uncertainty impacting Devices segment sales.

• Devices segment impacted by timing issues and regulatory uncertainty, while software segment margins normalized.

• Gross margin improved to 68.7% from 67.0% year-over-year, supported by high-margin AI revenue.

• EBITDA loss narrowed slightly to €-701k, with cost discipline offsetting lower revenue.

Financial highlights

• Q1 2026 revenue declined 16.7% year-over-year to €3.35 million; gross profit down 14.5%.

• EBITDA improved by 4.9% to -€701k, with EBITDA margin at -20.9%.

• Net loss narrowed to -€1.1 million from -€1.58 million; EPS improved to -0.05 from -0.08.

• Cash flow from operating activities was -€1.43 million, down from €371k in Q1 2025.

• Net debt at -€6.43 million, indicating a net cash position.

Outlook and guidance

• Expects full-year 2026 revenue growth compared to 2025, supported by Aurora AEYE and Lumo sales; guidance unchanged despite near-term visibility challenges.

• Software segment faces a challenging domestic market in Finland; weak Q1 puts pressure on subsequent quarters.

• Uncertainty in timing and size of large capital expenditure deals due to market dynamics and geopolitics.